Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
Ebiomedicine|June 21, 2016
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerJeri Kim, John W Davis, Eric A Klein, et al.
Nature Medicine|February 1, 2002
Steps toward mapping the human vasculature by phage displayWadih Arap, Mikhail G Kolonin, Martin Trepel, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Science Translational Medicine|December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot studySameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2014
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant studyMary-Ellen Taplin, Bruce Montgomery, Christopher J Logothetis, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2015
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3Ahmad Salameh, Alessandro K Lee, Marina Cardó-Vila, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2011
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patientsFernanda I Staquicini, Marina Cardó-Vila, Mikhail G Kolonin, et al.
Iscience|June 15, 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancersElavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
Ebiomedicine|June 21, 2016
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerJeri Kim, John W Davis, Eric A Klein, et al.
Nature Medicine|February 1, 2002
Steps toward mapping the human vasculature by phage displayWadih Arap, Mikhail G Kolonin, Martin Trepel, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Science Translational Medicine|December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot studySameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2014
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant studyMary-Ellen Taplin, Bruce Montgomery, Christopher J Logothetis, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2015
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3Ahmad Salameh, Alessandro K Lee, Marina Cardó-Vila, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2011
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patientsFernanda I Staquicini, Marina Cardó-Vila, Mikhail G Kolonin, et al.
Iscience|June 15, 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancersElavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Pageof 26